Vinyl Chemicals (I) Ltd: Intrinsic Value & Share Price Analysis

Share Price and Basic Stock Data

Last Updated: August 29, 2025, 7:22 pm

Quick Insight

Vinyl Chemicals (I) Ltd currently trades at a price of 271 with a market capitalization of 498 crore and a P/E ratio of 22.8, indicating the stock may be slightly overvalued. However, the company boasts a healthy ROE of 15.6% and ROCE of 21.1%, showcasing efficient capital allocation. With a low operating profit margin of 1.30%, there may be room for improvement in cost management. The strong balance sheet is evident with reserves of 125 crore and zero borrowings, contributing to a comfortable interest coverage ratio of 606.02x. Overall, despite the premium valuation, Vinyl Chemicals (I) Ltd's solid financial position and profitability metrics suggest a promising outlook for investors willing to hold for the long term.

Competitors of Vinyl Chemicals (I) Ltd

All Competitor Stocks of Vinyl Chemicals (I) Ltd

Quarterly Result

Last Updated: August 1, 2025, 9:25 am

Below is a detailed analysis of the quarterly data for Vinyl Chemicals (I) Ltd based on the most recent figures (Jun 2025) and their trends compared to the previous period:

• For Sales, as of Jun 2025, the value is 151.23 Cr.. The value appears to be declining and may need further review. It has decreased from 172.88 Cr. (Mar 2025) to 151.23 Cr., marking a decrease of 21.65 Cr..
• For Expenses, as of Jun 2025, the value is 149.26 Cr.. The value appears to be improving (decreasing) as expected. It has decreased from 162.93 Cr. (Mar 2025) to 149.26 Cr., marking a decrease of 13.67 Cr..
• For Operating Profit, as of Jun 2025, the value is 1.97 Cr.. The value appears to be declining and may need further review. It has decreased from 9.95 Cr. (Mar 2025) to 1.97 Cr., marking a decrease of 7.98 Cr..
• For OPM %, as of Jun 2025, the value is 1.30%. The value appears to be declining and may need further review. It has decreased from 5.76% (Mar 2025) to 1.30%, marking a decrease of 4.46%.
• For Other Income, as of Jun 2025, the value is 4.09 Cr.. The value appears strong and on an upward trend. It has increased from 0.19 Cr. (Mar 2025) to 4.09 Cr., marking an increase of 3.90 Cr..
• For Interest, as of Jun 2025, the value is 0.01 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 0.01 Cr..
• For Depreciation, as of Jun 2025, the value is 0.03 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 0.02 Cr. (Mar 2025) to 0.03 Cr., marking an increase of 0.01 Cr..
• For Profit before tax, as of Jun 2025, the value is 6.02 Cr.. The value appears to be declining and may need further review. It has decreased from 10.11 Cr. (Mar 2025) to 6.02 Cr., marking a decrease of 4.09 Cr..
• For Tax %, as of Jun 2025, the value is 26.08%. The value appears to be improving (decreasing) as expected. It has decreased from 28.09% (Mar 2025) to 26.08%, marking a decrease of 2.01%.
• For Net Profit, as of Jun 2025, the value is 4.45 Cr.. The value appears to be declining and may need further review. It has decreased from 7.27 Cr. (Mar 2025) to 4.45 Cr., marking a decrease of 2.82 Cr..
• For EPS in Rs, as of Jun 2025, the value is 2.43. The value appears to be declining and may need further review. It has decreased from 3.96 (Mar 2025) to 2.43, marking a decrease of 1.53.

Overall, while many items appear to show a positive trend, any significant downward movement warrant further investigation.

Profit & Loss - Annual Report

Last Updated: July 22, 2025, 2:45 pm

Growth

Last Updated: Unknown

Balance Sheet

Last Updated: August 11, 2025, 3:05 pm

Below is a detailed analysis of the balance sheet data for Vinyl Chemicals (I) Ltd based on the most recent figures (Mar 2025) and their trends compared to the previous period:

• For Equity Capital, as of Mar 2025, the value is 2.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2024) which recorded 2.00 Cr..
• For Reserves, as of Mar 2025, the value is 125.00 Cr.. The value appears strong and on an upward trend. It has increased from 115.00 Cr. (Mar 2024) to 125.00 Cr., marking an increase of 10.00 Cr..
• For Borrowings, as of Mar 2025, the value is 0.00 Cr.. The value remains steady. Additionally, since Reserves exceed Borrowings, this is considered a positive sign. There is no change compared to the previous period (Mar 2024) which recorded 0.00 Cr..
• For Other Liabilities, as of Mar 2025, the value is 135.00 Cr.. The value appears to be improving (decreasing). It has decreased from 188.00 Cr. (Mar 2024) to 135.00 Cr., marking a decrease of 53.00 Cr..
• For Total Liabilities, as of Mar 2025, the value is 262.00 Cr.. The value appears to be improving (decreasing). It has decreased from 305.00 Cr. (Mar 2024) to 262.00 Cr., marking a decrease of 43.00 Cr..
• For Fixed Assets, as of Mar 2025, the value is 1.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2024) which recorded 1.00 Cr..
• For CWIP, as of Mar 2025, the value is 0.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2024) which recorded 0.00 Cr..
• For Investments, as of Mar 2025, the value is 68.00 Cr.. The value appears strong and on an upward trend. It has increased from 57.00 Cr. (Mar 2024) to 68.00 Cr., marking an increase of 11.00 Cr..
• For Other Assets, as of Mar 2025, the value is 193.00 Cr.. The value appears to be declining and may need further review. It has decreased from 247.00 Cr. (Mar 2024) to 193.00 Cr., marking a decrease of 54.00 Cr..
• For Total Assets, as of Mar 2025, the value is 262.00 Cr.. The value appears to be declining and may need further review. It has decreased from 305.00 Cr. (Mar 2024) to 262.00 Cr., marking a decrease of 43.00 Cr..

Notably, the Reserves (125.00 Cr.) exceed the Borrowings (0.00 Cr.), indicating a solid financial buffer.

Overall, while many items appear to show a positive trend, any significant downward movement or items where Borrowings exceed Reserves warrant further investigation.

Cash Flow

Free Cash Flow

Financial Efficiency Indicators

Key Financial Ratios

After reviewing the key financial ratios for Vinyl Chemicals (I) Ltd, here is a detailed analysis based on the latest available data and recent trends:

• For FaceValue, as of Mar 25, the value is 1.00. This value is within the healthy range. There is no change compared to the previous period (Mar 24) which recorded 1.00.
• For Basic EPS (Rs.), as of Mar 25, the value is 12.17. This value is within the healthy range. It has increased from 11.91 (Mar 24) to 12.17, marking an increase of 0.26.
• For Diluted EPS (Rs.), as of Mar 25, the value is 12.17. This value is within the healthy range. It has increased from 11.91 (Mar 24) to 12.17, marking an increase of 0.26.
• For Cash EPS (Rs.), as of Mar 25, the value is 12.25. This value is within the healthy range. It has increased from 11.96 (Mar 24) to 12.25, marking an increase of 0.29.
• For Book Value[Excl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 69.22. It has increased from 63.66 (Mar 24) to 69.22, marking an increase of 5.56.
• For Book Value[Incl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 69.22. It has increased from 63.66 (Mar 24) to 69.22, marking an increase of 5.56.
• For Dividend / Share (Rs.), as of Mar 25, the value is 7.00. This value exceeds the healthy maximum of 3. It has increased from 6.75 (Mar 24) to 7.00, marking an increase of 0.25.
• For Revenue From Operations / Share (Rs.), as of Mar 25, the value is 341.67. It has increased from 325.45 (Mar 24) to 341.67, marking an increase of 16.22.
• For PBDIT / Share (Rs.), as of Mar 25, the value is 16.69. This value is within the healthy range. It has increased from 16.25 (Mar 24) to 16.69, marking an increase of 0.44.
• For PBIT / Share (Rs.), as of Mar 25, the value is 16.64. This value is within the healthy range. It has increased from 16.20 (Mar 24) to 16.64, marking an increase of 0.44.
• For PBT / Share (Rs.), as of Mar 25, the value is 16.61. This value is within the healthy range. It has increased from 16.17 (Mar 24) to 16.61, marking an increase of 0.44.
• For Net Profit / Share (Rs.), as of Mar 25, the value is 12.20. This value is within the healthy range. It has increased from 11.91 (Mar 24) to 12.20, marking an increase of 0.29.
• For PBDIT Margin (%), as of Mar 25, the value is 4.88. This value is below the healthy minimum of 10. It has decreased from 4.99 (Mar 24) to 4.88, marking a decrease of 0.11.
• For PBIT Margin (%), as of Mar 25, the value is 4.86. This value is below the healthy minimum of 10. It has decreased from 4.97 (Mar 24) to 4.86, marking a decrease of 0.11.
• For PBT Margin (%), as of Mar 25, the value is 4.86. This value is below the healthy minimum of 10. It has decreased from 4.96 (Mar 24) to 4.86, marking a decrease of 0.10.
• For Net Profit Margin (%), as of Mar 25, the value is 3.57. This value is below the healthy minimum of 5. It has decreased from 3.65 (Mar 24) to 3.57, marking a decrease of 0.08.
• For Return on Networth / Equity (%), as of Mar 25, the value is 17.62. This value is within the healthy range. It has decreased from 18.70 (Mar 24) to 17.62, marking a decrease of 1.08.
• For Return on Capital Employeed (%), as of Mar 25, the value is 23.89. This value is within the healthy range. It has decreased from 25.29 (Mar 24) to 23.89, marking a decrease of 1.40.
• For Return On Assets (%), as of Mar 25, the value is 8.51. This value is within the healthy range. It has increased from 7.15 (Mar 24) to 8.51, marking an increase of 1.36.
• For Long Term Debt / Equity (X), as of Mar 25, the value is 0.00. This value is below the healthy minimum of 0.2. There is no change compared to the previous period (Mar 24) which recorded 0.00.
• For Total Debt / Equity (X), as of Mar 25, the value is 0.00. This value is within the healthy range. There is no change compared to the previous period (Mar 24) which recorded 0.00.
• For Asset Turnover Ratio (%), as of Mar 25, the value is 2.20. It has decreased from 2.48 (Mar 24) to 2.20, marking a decrease of 0.28.
• For Current Ratio (X), as of Mar 25, the value is 1.93. This value is within the healthy range. It has increased from 1.62 (Mar 24) to 1.93, marking an increase of 0.31.
• For Quick Ratio (X), as of Mar 25, the value is 1.46. This value is within the healthy range. It has increased from 0.97 (Mar 24) to 1.46, marking an increase of 0.49.
• For Dividend Payout Ratio (NP) (%), as of Mar 25, the value is 0.00. This value is below the healthy minimum of 20. It has decreased from 83.94 (Mar 24) to 0.00, marking a decrease of 83.94.
• For Dividend Payout Ratio (CP) (%), as of Mar 25, the value is 0.00. This value is below the healthy minimum of 20. It has decreased from 83.55 (Mar 24) to 0.00, marking a decrease of 83.55.
• For Earning Retention Ratio (%), as of Mar 25, the value is 0.00. This value is below the healthy minimum of 40. It has decreased from 16.06 (Mar 24) to 0.00, marking a decrease of 16.06.
• For Cash Earning Retention Ratio (%), as of Mar 25, the value is 0.00. This value is below the healthy minimum of 40. It has decreased from 16.45 (Mar 24) to 0.00, marking a decrease of 16.45.
• For Interest Coverage Ratio (X), as of Mar 25, the value is 606.02. This value is within the healthy range. It has decreased from 611.00 (Mar 24) to 606.02, marking a decrease of 4.98.
• For Interest Coverage Ratio (Post Tax) (X), as of Mar 25, the value is 443.96. This value is within the healthy range. It has decreased from 448.62 (Mar 24) to 443.96, marking a decrease of 4.66.
• For Enterprise Value (Cr.), as of Mar 25, the value is 506.44. It has decreased from 574.53 (Mar 24) to 506.44, marking a decrease of 68.09.
• For EV / Net Operating Revenue (X), as of Mar 25, the value is 0.80. This value is below the healthy minimum of 1. It has decreased from 0.96 (Mar 24) to 0.80, marking a decrease of 0.16.
• For EV / EBITDA (X), as of Mar 25, the value is 16.58. This value exceeds the healthy maximum of 15. It has decreased from 19.27 (Mar 24) to 16.58, marking a decrease of 2.69.
• For MarketCap / Net Operating Revenue (X), as of Mar 25, the value is 0.82. This value is below the healthy minimum of 1. It has decreased from 0.97 (Mar 24) to 0.82, marking a decrease of 0.15.
• For Retention Ratios (%), as of Mar 25, the value is 0.00. This value is below the healthy minimum of 30. It has decreased from 16.05 (Mar 24) to 0.00, marking a decrease of 16.05.
• For Price / BV (X), as of Mar 25, the value is 4.09. This value exceeds the healthy maximum of 3. It has decreased from 4.97 (Mar 24) to 4.09, marking a decrease of 0.88.
• For Price / Net Operating Revenue (X), as of Mar 25, the value is 0.82. This value is below the healthy minimum of 1. It has decreased from 0.97 (Mar 24) to 0.82, marking a decrease of 0.15.
• For EarningsYield, as of Mar 25, the value is 0.04. This value is below the healthy minimum of 5. It has increased from 0.03 (Mar 24) to 0.04, marking an increase of 0.01.

Overall, while many metrics show healthy performance, any figures highlighted in red or significant downward trends warrant further investigation.

Fair Value

*Investments are subject to market risks

Strength and Weakness